logo
Tinnitus: 'Where is this ringing in my ears coming from?'

Tinnitus: 'Where is this ringing in my ears coming from?'

BBC News08-02-2025
Oliver Moazezzi was working from home when he first heard a loud ringing in his ears."I had an anxiety attack. I went from near perfect hearing to having hearing loss and tinnitus. I was hugely depressed," he said.He describes his experience as a "journey down a long road to self-discovery" after struggling to find the right support and treatment from health professionals. A new report by Tinnitus UK estimates eight million people in the UK will be affected by tinnitus by the end of 2025.
If he is lucky, Mr Moazezzi says his tinnitus sounds like a "hiss", otherwise it can sound like a very unpleasant "high-pitched scream". Initially after speaking to his GP, the Hampshire-based IT consultant said he felt helpless because they did not understand how bad it was. So he decided to see if he could measure how loud the ringing was by using a combination of apps on his phone and TV.
Sound masking is a method used by people with tinnitus which uses white noise like rainfall or wind to mask the sound they are experiencing. Mr Moazezzi played white noise on his TV and kept turning the volume up until he could no longer hear his tinnitus. Then he used a decibel meter on his phone to measure how loud the sound was coming from his TV. "At one point it was like 90 decibels. It was consistently between 40 and I think 67 for a period of time," he told the BBC."But I essentially had 40 to 90 decibels of tinnitus for about two-and-a-half months."He says it was only after doing his own research that he managed to lower it to a milder level and for it to become more manageable.He said: "I found lots of information online. Seeing how many famous people suffer with it I got a greater understanding of how they actually function. I eventually came to the realisation that maybe I can function too."
Sonja Jones is an audiologist and part of the scientific advisory board for Tinnitus UK - she is also one of the authors of the report. She explained current continuing professional development (CPD) was not good enough and for a number of private clinics tinnitus was a low priority. "We're seeing systemic issues from the ground up all over the audiology industry. From the training on day one of audiology school to the post-qualification training. These aren't standardised so no-one is necessarily singing from the same sheet," she said.The report also highlighted long delays in NHS tinnitus care, with clinicians reporting waiting times of up to 12 months for psychology, talking therapies, CBT referrals or hearing aid assistance and three years for ENT appointments.
Eventually after testing, Mr Moazezzi was told he had lost some of his hearing in both ears - and like lots of people when they experience ringing sounds for the first time searched for answers."I work from home and I don't expose myself to loud noises very often at all."I found that some of the antibiotics I had been taking were ototoxic. My ENT specialist said this could have contributed but there's no way of proving any of those things," he added.Don McFerran, president of Tinnitus UK, is an ENT surgeon with a sub-specialty interest in otology and, in particular, tinnitus.He said: "Most medications do not cause tinnitus (are not ototoxic), but there are some exceptions. Drugs that contain platinum, certain antibiotics, and some other medications can have ototoxic effects."But for Mr Moazezzi he said it was all about making people aware of how important our ears are. "I'm just trying to get the message out there to help people protect themselves. Obviously not everyone can prevent themselves getting it but like exercise it's preventative maintenance," he said.
If you have been affected by anything in this article you can contact the BBC Action Line at www.bbc.co.uk/actionline
You can follow BBC Hampshire & Isle of Wight on Facebook, X, or Instagram.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NHS push to stamp out ‘silent killer' with at-home testing
NHS push to stamp out ‘silent killer' with at-home testing

The Independent

timean hour ago

  • The Independent

NHS push to stamp out ‘silent killer' with at-home testing

The NHS has identified 225 individuals with hepatitis C following its national at-home testing service, launched in May 2023. Over 100,000 at-home hepatitis C tests have been requested since the service began, including a surge after the Infected Blood Inquiry's final report in May 2024. Hepatitis C, often called a 'silent killer', can lead to severe liver damage if undiagnosed, but is treatable with antiviral tablets. Among those diagnosed, seven in ten are from deprived communities, with common risk factors including injecting drug use, though a small number are linked to contaminated blood. NHS England has also introduced a system for new GP registrants to identify those who received blood transfusions before 1996, aiming to find more victims of the infected blood scandal.

Doggy 'Mounjaro' could be the next solution for treating pudgy pets
Doggy 'Mounjaro' could be the next solution for treating pudgy pets

Daily Record

timean hour ago

  • Daily Record

Doggy 'Mounjaro' could be the next solution for treating pudgy pets

A new form of pet health care may be on the horizon as scientists sniff around weight loss drugs for dogs. With many people wanting to lose weight across the globe, drugs such as Mounjaro have become a household name. Helping people manage their weight, those on a health kick along with the medication are able to learn how to eat healthier and have a better lifestyle. ‌ Following on from their apparent success, researchers are now turning their view to a different form of clientele that they believe may be in need of a detox. While many of us see our four-legged friends as perfect no matter how they look, it turns out that up to 60 per cent of dogs in the UK are classed as obese or overweight. ‌ With this startling stat, some scientists feel like there is room in the market for weight loss drugs for dogs. And it may not be too far on the horizon. ‌ San Francisco-based bio-phama company Okava have set their sites on the new frontier of pet health and are planning to run trials of a drug that will mimic the effects of medications like Ozempic. The end goal is to create an implant version of the drug for dogs, which will last for six months at a time. Ozempic is not marketed as a weight loss drug but one to prescribed to type 2 diabetes patients to help manage their condition by controlling blood sugar levels alongside other medications and lifestyle changes. However, it has gained popularity and attention for its potential role in weight loss, which can be a side effect of the drug's appetite-controlling abilities. With hopes of have the canine weight loss drug available as early as 2028 or 2029, the US company estimates the current market for this product could be worth up to $10billion. ‌ In terms of the human version, the drugs mimic a natural hormone called GLP-1 which regulates blood sugar and appetite. In Mounjaro is active ingredient is called tirzepatide, whereas Ozempic uses semaglutide. The ultimate goal of these ingredients is to leave users feeling fuller for longer, which will end up reducing their overall food intake. ‌ As scientists try to mimic this hormone for dogs, it is hoped that the drug will help reduce the begging behaviour of our furry pals, which many owners find hard to resist. However, researchers will need to make sure they find the right balance with the drug as a lack of appetite in our canine companions is normally associated with being unwell. This isn't the first weight loss drug that has been created for pets, as Slentrol was released in 2007. However, this creation didn't end up selling well, partly due to owners believing their pets seemed ill while on the medication. ‌ However, Okava's chief executive Michael Klotsman hopes that any behavioural changes in dogs while using their drug will be quite different. The planned implant by Okava has been named OKV-119 and will contain a GLP-1 mimic called exenatide. Michael told The Guardian: "What owners should expect to see is their pet eating appropriate portions without the previous food obsession – they'll still eat regularly and show interest in meals, just without the excessive begging, scavenging or gulping behaviour." ‌ However, not everyone is fully on board with the idea. Many vets are instead advising that overweight dogs, in most cases, are able to lose the extra pounds through more exercise and a restricted diet Caroline Allen, chief veterinary officer at the RSPCA told The Independent: "A healthy diet and exercise is the best way to keep our pets happy and well but we understand that owners can sometimes struggle to manage their pets' weight. "There is currently little information about proposed weight-loss implants or vaccinations for animals, and owners shouldn't rely on them becoming available. "Before resorting to these sorts of interventions, owners should seek help from their vet about how to reduce their pet's weight with a good diet and providing lots of opportunities to exercise and play in ways that their pet will enjoy." She added: "It may be that weight loss jabs or implants may have a role to play in future in very limited circumstances where animals are clinically unwell, but the best thing we can do is set healthy habits from the start so our pets can live the best life possible." Join the Daily Record WhatsApp community!

NHS update for people with heart and CVD problems explained
NHS update for people with heart and CVD problems explained

Daily Record

time3 hours ago

  • Daily Record

NHS update for people with heart and CVD problems explained

New draft guidance from the National Institute for Health and Care Excellence will see six online platforms conditionally recommended to support adults Heart patients will be able to undertake rehabilitation online from their own homes instead of waiting for face-to-face appointments after several platforms received conditional approval for NHS use. Specialists said the programmes 'offer real potential to transform' how this type of care is delivered. ‌ Six online platforms have been conditionally recommended to support adults with cardiovascular disease (CVD) in new draft guidance from the National Institute for Health and Care Excellence (NICE). These are Activate Your Heart, D REACH-HF, Digital Heart Manual, Gro Health HeartBuddy, KiActiv and myHeart. ‌ CVD is a general term for conditions that impact the heart or blood vessels. It is estimated to impact approximately seven million people in the UK. ‌ Even still, according to NICE, uptake for cardiac rehabilitation programmes, which can reduce the risk of further heart problems and hospital admissions, is low. Each platform is now designed to offer cardiac rehabilitation online, including exercise programmes, diet advice, medication management, and psychological support. Some of the platforms also include wearable devices to monitor activity levels. Dr Anastasia Chalkidou, healthtech programme director at NICE, said: "These digital platforms offer real potential to transform how cardiac rehabilitation is offered to people to meet their individual circumstances. "We know that traditional programmes aren't reaching everyone who could benefit – particularly women, younger patients and people from ethnic minority backgrounds." Before the online platforms are offered as an option, patients must be assessed by a healthcare professional. NICE suggests that further support may be needed for older people, those with disabilities, homeless patients, or those whose first language is not English. The six platforms will be used on the NHS over the next three years to generate more evidence and data on their long-term effectiveness. Dr Chalkidou added: "The early data is promising and suggests, with safeguards in place, more people should now be given the opportunity to use these new technologies. "This three-year evidence collection period will give us the additional robust data we need to determine whether these innovations should be recommended as a permanent part of cardiac care." A consultation on the conditional recommendation is now underway and will close on September 3. NICE said seven other platforms - Beat Better, Datos Health, Get Ready, Luscii Vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health, and Sword Move - require more research before they can be funded by the NHS.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store